← Leaderboards
David Trentham
Beth Israel Deaconess Medical Center
$775,664
Attributed
$775,664
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$775,664 · 3
By mechanism
M01$775,664 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Susan L Greenspan$27,746,173
- George C Tsokos$40,494,511
- Steven C. Schachter$10,007,385
- Bruce J Dezube$965,277
- K Lea Sewell$387,832
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectSkeletal Disorder ChemotherapyCollagenOral AdministrationChild (0-11)Clinical TrialsAntirheumatic AgentsJuvenile Rheumatoid ArthritisAntibody FormationAutoantibodyRheumatoid ArthritisDrug Screening /EvaluationClinical Trial Phase IArthritis TherapyDrug Adverse EffectPlacebosAntiinflammatory Agents
Grant awards (9)
OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
Therafectin compared to placebo in patients with rheumatoid arthritis$193,916
M01 · FY2000 · RR
Therafectin compared to placebo in patients with rheumatoid arthritis$193,916
M01 · FY2000 · RR
COMPARISON OF ORAL COLLORAL WITH PLACEBO IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS$193,916
M01 · FY2000 · RR
COMPARISON OF ORAL COLLORAL WITH PLACEBO IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS$193,916
M01 · FY2000 · RR
OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
OPEN LABEL STUDY OF ORAL TYPE II COLLAGEN IN JUVENILE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR